The County Durham & Darlington or Tees DO NOT PRESCRIBE List can be accessed online at: http://medicines.necsu.nhs.uk/guidelines/durhamdarlington or
The County Durham & Darlington or Tees GREY List – items to be prescribed in certain specific circumstances only can be accessed online at: http://medicines.necsu.nhs.uk/guidelines/durham-darlington or https://medicines.necsu.nhs.uk/guidelines/tees-guidelines/
CD&D Patient Decision Aids Resource available at: http://medicines.necsu.nhs.uk/guidelines/durham-darlington/
15 mg,2mg,3mg,6mg Suppositories
Restricted Paediatrics only
Various strengths available. Not routinely stocked at STHFT ordered asd needed.
Dermatology use in alopecia only
For use by endocrinology for gustatory sweating or dermatology for hyperhidrosis
Due to short expiry ordered as required
Lidocaine 4% Adrenaline 0.1% Tetracaine0.5% gel
For use by ENT only for facial alceration or grommet insertion
For pre-eclampsia, eclampsia and pre-term labour
For use in cystinosis on specialist advice only
For the removal of eschar in adults with deep partial and full thickness thermal burns to a maximum of 15% TBSA.
Remdesivir 100 mg concentrate for solution for infusion (each vial contains 100 mg of remdesivir, each mL of concentrate contains 5 mg of remdesivir).
Remdesivir 100 mg powder for concentrate for solution for infusion (each vial contains 100 mg of remdesivir, after reconstitution, each vial contains 5 mg/mL of remdesivir solution).
Unlicensed medicine - named patient use only
Following confirmation of a Conditional Marketing Authorisation (CMA) by the European Medicines Agency (EMA) for the use of remdesivir in the treatment of COVID-19, the scientific opinion given for remdesivir via the Early Access to Medicines Scheme (EAMS) put in place on 26th May 2020 has now lapsed.
From 3 July 2020, an interim clinical commissioning policy has been put in place to define routine access to remdesivir in the treatment of COVID-19 across the UK. The policy reflects the conditions of the CMA, but also includes secondary criteria to be used should there be limitations in the supply of remdesivir in the UK.
Further information can be found in the attached alert; the interim clinical commissioning policy is also attached: https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=103063
Commissioner = CCG, tariff included.